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Chinese scientists and US leadership in the 
life sciences
To the Editor — We, the undersigned, 
are leaders in US academic and industrial 
biomedical research and drug development. 
We are concerned that recent actions by 
government agencies and universities with 
respect to Chinese scientists in the United 
States could threaten US leadership in 
biomedical science.
Recently, some scientists from China, 
or American-born researchers of Chinese 
heritage, have been summarily dismissed 
from their university positions, creating 
a climate of fear and uncertainty in our 
biomedical communities.
Let us be clear: we must absolutely guard 
against foreign espionage and intellectual 
property theft, and prosecute those who 
engage in it, whatever their origins. At 
the same time, actions that more broadly 
limit collaboration between Chinese and 
American scientists and companies would 
be deleterious to our national interests; so 
too would limitations on American residents 
of Chinese origin receiving government 
research funding or being employed by the 
US National Institutes of Health.
In military wars between national 
adversaries, leaders often vilify ‘the 
other’. Our ‘war’ unifies an international 
community of medical researchers to fight 
a common adversary, disease: cancers, 
immune diseases, Alzheimer’s disease and 
infections, to name just a few. Vilifying or 
excluding any group as ‘the other’ limits our 
ability to win this war.
The United States’ unique constitution 
as a nation of immigrants has been 
fundamental to our world leadership in 
biomedical research and drug development. 
Our nation most prolifically attracts the 
best, most diverse talent from the entire 
world. This has enriched our economy and 
society. As a case in point, our preliminary 
research indicates that, since 1999, over 
400,000 US patents have been issued to 
inventors of Chinese descent resident in 
the United States (Fig. 1), and ~28% of US 
biomedical science publications in 2018 
included an author of Chinese descent (see 
Supplementary Methods and Supplementary 
Data 1 and 2).
An atmosphere of intimidation will 
encourage many outstanding scientists of 
Chinese origin to leave the United States or 
never to come. In addition, scientists from 
other countries who are working in the 
United States cannot fail to get the message 
that they may well be next.
We also note that the vast majority of 
the results of academic biomedical research 
are not secret; their publication and open 
exchange are the cornerstone of our success 
against our common enemy of human 
disease and suffering. Thomas Jefferson 
wrote, “He who receives an idea from 
me, receives instruction himself without 
lessening mine; as he who lights his taper at 
mine, receives light without darkening me.”
We support the opinions recently 
published by the editors of Nature (571, 
297, 2019) and Nature Biotechnology (37, 
827, 2019) and by former US National 
Institutes of Health director Elias Zerhouni 
in Science (365, 9, 2019), and advocate for 
measured policies that will both protect US 
intellectual property and continue to foster 
the diversity and collaboration that fuel our 
ability to advance science and cure disease. 
At a minimum, universities must effectively 
communicate and consistently apply their 
rules governing scientific collaborations 
and intellectual property obligations, and 
they, as well as government agencies, must 
clearly justify their actions when they accuse 
scientists of malfeasance or seek to dismiss 
them from their positions.
Ronald Reagan said, “We lead the world, 
because unique among nations, we draw 
our people, our strength from every country 
and every corner of the world,” and, “If we 
ever close our door to new Americans, our 
leadership in the world will soon be lost.”
Nowhere are these thoughts more 
pertinent than in biomedical science. If 
we are to prevail in humanity’s common 
quest to conquer disease, our surest route 
is to include any person able to contribute, 
regardless of country of origin, religion, 
race, gender or other identity. The US 
biomedical community stands for the 
principles of diversity and unity embedded 
in the founding principles of our country, 
without which our leadership indeed will 
soon be lost. ❐
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Fig. 1 | Estimating the contribution of Chinese-ethnic researchers to the US patent landscape.  
US-resident inventors with top 200 Chinese ethnic names as a percentage of total US inventors.
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